BRAF and neoplasm: Similar to what was observed in Braf/Pten tumor-draining ILNs, MC903 treatment–promoted GATA3+ Tregs in Braf ELNs exhibited signature expression of ST2, OX40, and PD-1 (Figure 4G), but not IL-4 and IL-13 which were only detected in GATA3+ Th2 cells (Figure 4G).